{"nctId":"NCT03785405","briefTitle":"Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF","startDateStruct":{"date":"2019-05-02","type":"ACTUAL"},"conditions":["Heart Failure"],"count":216,"armGroups":[{"label":"sacubitril/valsartan","type":"EXPERIMENTAL","interventionNames":["Drug: sacubitril/valsartan"]}],"interventions":[{"name":"sacubitril/valsartan","otherNames":["LCZ696"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent\n* On study drug at PANORAMA-HF Part 2 EOS visit. Does not have any significant safety issue\n\nExclusion Criteria:\n\n* Subject only participated in PANORAMA-HF Part 1 or was a SF in PANORAMA-HF or permanently discontinued study drug in PANORMA-HF Part 2\n* Use of investigational drugs within 5 half-lives of enrollment or within 30 days (longer duration); with the exception of PANORAMA-HF study drug (requires \\>/=36-hour washout before baseline visit)\n* History of hypersensitivity or allergy to study treatment, its excipients or drugs of similar chemical class, ACEIs, ARBs, or NEP inhibitor and known/suspected contraindications to sacubitril/valsartan\n* Renal vascular hypertension (including renal artery stenosis)\n* Significant renal estimated glomerular filtration rate disorder (eGFR calculated using modified Schwartz formula \\<30% mean GFR for age); hepatic disorder (serum aspartate aminotransferase or alanine aminotransferase \\> 3 times upper limit of normal); gastrointestinal disorder or biliary disorder\n* History of angioedema\n* Parents or legal guardians of subject who do not give consent or allow the child to give assent, or inability of patient or parents/legal guardians to follow instructions or comply with follow-up procedures\n* Any medical condition(s) that may put the patient at risk in the investigator's opinion or that the investigator deems unsuitable for the study\n* Other protocol defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Number of participants with at least one Adverse Events (AEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events","description":"Number of participants with at least one Serious Adverse Events (SAEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"PRIMARY","title":"Duration of Drug Exposure","description":"Median duration of exposure to sacubitril/valsartan (including temporary interruptions)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"894","spread":null},{"groupId":"OG001","value":"951","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":59,"n":130},"commonTop":["COVID-19","Cough","Pyrexia","Upper respiratory tract infection","Vomiting"]}}}